1227799-59-8

Basic information

• Product Name: bis[O-(14-benzoylaconin-8-yl)] azelate
• Synonyms: bis[O-(14-benzoylaconin-8-yl)] azelate
• CAS NO: 1227799-59-8
• Molecular Weight: 1359.61
• Mol File: 1227799-59-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: bis[O-(14-benzoylaconin-8-yl)] azelate(CAS DataBase Reference)
• NIST Chemistry Reference: bis[O-(14-benzoylaconin-8-yl)] azelate(1227799-59-8)
• EPA Substance Registry System: bis[O-(14-benzoylaconin-8-yl)] azelate(1227799-59-8)

Safety Data

• Hazardous Substances Data: 1227799-59-8(Hazardous Substances Data)

Upstream product

• 123-99-9 azelaic acid 
• 302-27-2 indaconitine 

Relevant articles and documents

Hemisynthesis and antiproliferative properties of mono-[O-(14- benzoylaconine-8-yl)]esters and bis-[O-(14-benzoylaconine-8-yl)]esters

A series of mono- and bifunctional acyl compounds, build from the 8-O-azeloyl-14-benzoylaconine scaffold and differing by the length of the alkyl linker chain, were synthesised and evaluated against a panel of human tumour cell lines, A-549 (lung cancer), MCF-7 (breast cancer) and HCT-15 (colon cancer). None of the mono-[O-(14-benzoylaconine-8-yl)]esters displayed in vitro activity against tumour cells (IC50 > 60 μM). However, three bis-[O-(14-benzoylaconine-8-yl)]esters presented a noticeable in vitro cytotoxic activity, those bearing 7, 8 and 9 carbon atoms between the two aconitine moieties, with IC50s ranging between 4 and 28 μM. The most active, bis[O-(14-benzoylaconine-8-yl)]suberate, was then evaluated in vivo in immunodeficient mice bearing human tumour xenografts originating from MCF-7 and HCT-15 cells. For MCF-7 cells, administration of five doses every 4 days, and weekly administration of 4 doses resulted in T/C percent values of 36% (p = 0.001) and 56% (p = 0.02) on day 45, respectively. For HCT-15 cells, administration of five doses every 3 days resulted in 49% tumour regression on the 25th day (p = 0.00001).